PBYIPuma Biotechnology
About Puma Biotechnology
Puma Biotechnology (NASDAQ:PBYI) is a biopharmaceutical company focused on developing and commercializing innovative products to enhance cancer care. It specializes in acquiring and developing novel therapeutics for the treatment of various forms of cancer. One of its key projects includes the development of neratinib, an oral medication designed for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy. Puma Biotechnology aims to advance its research and development efforts to introduce new cancer therapies that can potentially improve patient outcomes and quality of life. Its objectives include expanding the indications for its existing products, advancing its pipeline through clinical trials, and seeking strategic partnerships to enhance its operational capabilities and market reach.
What is PBYI known for?
Snapshot
Public US
Ownership
2007
Year founded
185
Employees
Los Angeles, United States
Head office
1 of 2
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Los Angeles, US
Products and/or services of Puma Biotechnology
- Neratinib (Nerlynx) - An oral tyrosine kinase inhibitor used for the treatment of HER2-positive breast cancer.
- Breast cancer clinical trials - Ongoing trials to explore the efficacy of neratinib in various settings.
- Extended adjuvant treatment research - Studies focused on improving outcomes for early-stage HER2-positive breast cancer patients.
- HER2 mutation-targeted therapies - Developing treatments specifically for patients with HER2 mutations.
- Global expansion efforts - Expanding the availability of their flagship product, Nerlynx, into new markets.
- Patient support programs - Offering educational and financial support to patients undergoing treatment with their products.
Puma Biotechnology executive team
- Mr. Alan H. AuerbachFounder, Chairman, President, CEO & Secretary
- Mr. Maximo F. NouguesCFO & Principal Accounting Officer
- Mr. Douglas Hunt B.Sc., FRAPSChief Regulatory Affairs, Medical Affairs, Pharmacovigilance & Law Officer
- Mr. Mariann OhanesianSenior Director of Investor Relations
- Ms. Heather BlaberSenior Vice President of Marketing
- Mr. Roger L. StormsSenior Vice President of Sales